Impairment of Adipose Tissue in Prader-Willi Syndrome Rescued by Growth Hormone Treatment

Overview

Journal Int J Obes (Lond)

Specialty Endocrinology

Date 2014 Jan 11

PMID 24406482

Citations 13

Authors

T Cadoudal

M Buleon

C Sengenes

G Diene

F Desneulin

C Molinas

S Eddiry

F Conte-Auriol

D Daviaud

P G P Martin

A Bouloumie

J-P Salles

M Tauber

P Valet

Affiliations

Soon will be listed here.

Abstract

Background: Prader-Willi syndrome (PWS) results from abnormalities in the genomic imprinting process leading to hypothalamic dysfunction with an alteration of growth hormone (GH) secretion. PWS is associated with early morbid obesity and short stature which can be efficiently improved with GH treatment.

Objectives: Our aims were to highlight adipose tissue structural and functional impairments in children with PWS and to study the modifications of those parameters on GH treatment.

Subjects And Methods: Plasma samples and adipose tissue biopsies were obtained from 23 research centers in France coordinated by the reference center for PWS in Toulouse, France. Lean controls (n=33), non-syndromic obese (n=53), untreated (n=26) and GH-treated PWS (n=43) children were enrolled in the study. Adipose tissue biopsies were obtained during scheduled surgeries from 15 lean control, 7 untreated and 8 GH-treated PWS children.

Results: Children with PWS displayed higher insulin sensitivity as shown by reduced glycemia, insulinemia and HOMA-IR compared with non-syndromic obese children. In contrast, plasma inflammatory cytokines such as TNF-α, MCP-1 and IL-8 were increased in PWS. Analysis of biopsies compared with control children revealed decreased progenitor cell content in the stromal vascular fraction of adipose tissue and an impairment of lipolytic response to β-adrenergic agonist in PWS adipocytes. Interestingly, both of these alterations in PWS seem to be ameliorated on GH treatment.

Conclusion: Herein, we report adipose tissue dysfunctions in children with PWS which may be partially restored by GH treatment.

Citing Articles

Sex dimorphic associations of Prader-Willi imprinted gene expressions in umbilical cord with prenatal and postnatal growth in healthy infants.

Mas-Pares B, Carreras-Badosa G, Gomez-Vilarrubla A, De Arriba-Munoz A, Lafalla-Bernard O, Prats-Puig A World J Pediatr. 2025; 21(1):100-112.

PMID: 39838229 PMC: 11813995. DOI: 10.1007/s12519-024-00865-4.

The Effects of Growth Hormone Treatment Beyond Growth Promotion in Patients with Genetic Syndromes: A Systematic Review of the Literature.

Kucharska A, Witkowska-Sedek E, Erazmus M, Artemniak-Wojtowicz D, Krajewska M, Pyrzak B Int J Mol Sci. 2024; 25(18).

PMID: 39337654 PMC: 11432634. DOI: 10.3390/ijms251810169.

Adipose Tissue Hyperplasia and Hypertrophy in Common and Syndromic Obesity-The Case of BBS Obesity.

Horwitz A, Birk R Nutrients. 2023; 15(15).

PMID: 37571382 PMC: 10421039. DOI: 10.3390/nu15153445.

CD16 monocytes are involved in the hyper-inflammatory state of Prader-Willi Syndrome by single-cell transcriptomic analysis.

Xu Y, Hou X, Guo H, Yao Z, Fan X, Xu C Front Immunol. 2023; 14:1153730.

PMID: 37251380 PMC: 10213932. DOI: 10.3389/fimmu.2023.1153730.

Ghrelin Levels in Children With Intestinal Failure Receiving Long-Term Parenteral Nutrition.

Vlug L, Delhanty P, Neelis E, Huisman M, Visser J, Rings E Front Nutr. 2022; 9:896328.

PMID: 35634374 PMC: 9131070. DOI: 10.3389/fnut.2022.896328.

References

Hauffa B, Haase K, Range I, Unger N, Mann K, Petersenn S . The effect of growth hormone on the response of total and acylated ghrelin to a standardized oral glucose load and insulin resistance in children with Prader-Willi syndrome. J Clin Endocrinol Metab. 2006; 92(3):834-40. DOI: 10.1210/jc.2006-1011. View

Le Cao K, Boitard S, Besse P . Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems. BMC Bioinformatics. 2011; 12:253. PMC: 3133555. DOI: 10.1186/1471-2105-12-253. View

Burman P, Ritzen E, Lindgren A . Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr Rev. 2001; 22(6):787-99. DOI: 10.1210/edrv.22.6.0447. View

Smith A, Egan J, Ridley G, Haan E, Montgomery P, Williams K . Birth prevalence of Prader-Willi syndrome in Australia. Arch Dis Child. 2003; 88(3):263-4. PMC: 1719461. DOI: 10.1136/adc.88.3.263. View

Arner P . Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract Res Clin Endocrinol Metab. 2005; 19(4):471-82. DOI: 10.1016/j.beem.2005.07.004. View

Nicholls R, Knepper J . Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. Annu Rev Genomics Hum Genet. 2001; 2:153-75. DOI: 10.1146/annurev.genom.2.1.153. View

Olefsky J, Glass C . Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010; 72:219-46. DOI: 10.1146/annurev-physiol-021909-135846. View

Schuster D, Osei K, Zipf W . Characterization of alterations in glucose and insulin metabolism in Prader-Willi subjects. Metabolism. 1996; 45(12):1514-20. DOI: 10.1016/s0026-0495(96)90181-x. View

Goldstone A . Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab. 2003; 15(1):12-20. DOI: 10.1016/j.tem.2003.11.003. View

10.

Cassidy S, Schwartz S, Miller J, Driscoll D . Prader-Willi syndrome. Genet Med. 2012; 14(1):10-26. DOI: 10.1038/gim.0b013e31822bead0. View

11.

Bush J, Wevrick R . Loss of the Prader-Willi obesity syndrome protein necdin promotes adipogenesis. Gene. 2012; 497(1):45-51. DOI: 10.1016/j.gene.2012.01.027. View

12.

Vogels A, Van den Ende J, Keymolen K, Mortier G, Devriendt K, Legius E . Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Eur J Hum Genet. 2003; 12(3):238-40. DOI: 10.1038/sj.ejhg.5201135. View

13.

Diene G, Mimoun E, Feigerlova E, Caula S, Molinas C, Grandjean H . Endocrine disorders in children with Prader-Willi syndrome--data from 142 children of the French database. Horm Res Paediatr. 2010; 74(2):121-8. DOI: 10.1159/000313377. View

14.

Carey D, Jenkins A, Campbell L, Freund J, Chisholm D . Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes. 1996; 45(5):633-8. DOI: 10.2337/diab.45.5.633. View

15.

Hoybye C, Hilding A, Jacobsson H, Thoren M . Growth hormone treatment improves body composition in adults with Prader-Willi syndrome. Clin Endocrinol (Oxf). 2003; 58(5):653-61. DOI: 10.1046/j.1365-2265.2003.01769.x. View

16.

Butler J, Whittington J, Holland A, McAllister C, Goldstone A . The transition between the phenotypes of Prader-Willi syndrome during infancy and early childhood. Dev Med Child Neurol. 2010; 52(6):e88-93. DOI: 10.1111/j.1469-8749.2009.03530.x. View

17.

Costeff H, Holm V, Ruvalcaba R, Shaver J . Growth hormone secretion in Prader-Willi syndrome. Acta Paediatr Scand. 1990; 79(11):1059-62. DOI: 10.1111/j.1651-2227.1990.tb11383.x. View

18.

Swaab D . Prader-Willi syndrome and the hypothalamus. Acta Paediatr Suppl. 1997; 423:50-4. DOI: 10.1111/j.1651-2227.1997.tb18369.x. View

19.

Carrel A, Myers S, Whitman B, Allen D . Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study. J Pediatr. 1999; 134(2):215-21. DOI: 10.1016/s0022-3476(99)70418-x. View

20.

Hoybye C . Inflammatory markers in adults with Prader-Willi syndrome before and during 12 months growth hormone treatment. Horm Res. 2006; 66(1):27-32. DOI: 10.1159/000093229. View